Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocuphire Pharma, Inc. (NASDAQ: OCUP) on April 21, 2023, covering events that occurred on April 19, 2023. The filing addresses significant changes to the company's executive leadership and board committee composition.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial information disclosed relates to executive compensation:
- Interim CEO Salary: $40,000 per month.
- Equity Grant: 50,000 restricted stock units (RSUs) vesting 12 months post-grant.
- Bonus: Eligible for a potential prorated bonus at the Board's discretion.
Material Changes
The primary material change reported is the termination of Mina Sooch as President and Chief Executive Officer, effective April 19, 2023. Concurrently, the Board appointed Richard Rodgers as Interim President and Chief Executive Officer. Additionally, the Board composition was adjusted: Richard Rodgers resigned from the Compensation and Audit Committees, Cam Gallagher was appointed to the Audit Committee, and James Manuso was appointed Chair of the Audit Committee.
Outlook, Risks, and Management Commentary
The filing references a press release issued on April 21, 2023, regarding the leadership changes, which is incorporated by reference. The document does not contain specific forward-looking guidance, risk factors, or management commentary regarding the company's operational outlook beyond the leadership transition. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the terms of the separation agreement for the former CEO, Mina Sooch, which are not detailed in this filing.
- Review the attached press release (Exhibit 99.1) for strategic context regarding the leadership change.
- Monitor future filings for the appointment of a permanent CEO and any resulting changes to the company's strategic direction.
- Confirm the impact of the interim CEO's equity grant on total shareholder dilution.